Enzyme-Activated Multifunctional Prodrug Combining Site-Specific Chemotherapy with Light-Triggered Photodynamic Therapy

2022 ◽  
Author(s):  
Hong-Xia Zhang ◽  
Hao-Hua Lin ◽  
Dan Su ◽  
De-Chao Yang ◽  
Jian-Yong Liu
Keyword(s):  
Photodynamic Therapy ◽  
Site Specific

scholarly journals Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tumors

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 428
Author(s):  
Emma Renard ◽  
Estel Collado Camps ◽  
Coline Canovas ◽  
Annemarie Kip ◽  
Martin Gotthardt ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Fluorescence Imaging ◽  
Ex Vivo ◽  
Growth Factor Receptor ◽  
Nuclear Imaging ◽  
A431 Cells ◽  
Site Specific ◽  
Variable Domains ◽  
Diagnostic Probe

Variable domains of heavy chain only antibodies (VHHs) are valuable agents for application in tumor theranostics upon conjugation to both a diagnostic probe and a therapeutic compound. Here, we optimized site-specific conjugation of the chelator DTPA and the photosensitizer IRDye700DX to anti-epidermal growth factor receptor (EGFR) VHH 7D12, for applications in nuclear imaging and photodynamic therapy. 7D12 was site-specifically equipped with bimodal probe DTPA-tetrazine-IRDye700DX using the dichlorotetrazine conjugation platform. Binding, internalization and light-induced toxicity of DTPA-IRDye700DX-7D12 were determined using EGFR-overexpressing A431 cells. Finally, ex vivo biodistribution of DTPA-IRDye700DX-7D12 in A431 tumor-bearing mice was performed, and tumor homing was visualized with SPECT and fluorescence imaging. DTPA-IRDye700DX-7D12 was retrieved with a protein recovery of 43%, and a degree of labeling of 0.56. Spectral properties of the IRDye700DX were retained upon conjugation. 111In-labeled DTPA-IRDye700DX-7D12 bound specifically to A431 cells, and they were effectively killed upon illumination. DTPA-IRDye700DX-7D12 homed to A431 xenografts in vivo, and this could be visualized with both SPECT and fluorescence imaging. In conclusion, the dichlorotetrazine platform offers a feasible method for site-specific dual-labeling of VHH 7D12, retaining binding affinity and therapeutic efficacy. The flexibility of the described approach makes it easy to vary the nature of the probes for other combinations of diagnostic and therapeutic compounds.

A bioorthogonally activatable photosensitiser for site-specific photodynamic therapy

2020 ◽  
Vol 56 (7) ◽  
pp. 1078-1081 ◽  
Author(s):  
Yimin Zhou ◽  
Roy C. H. Wong ◽  
Gaole Dai ◽  
Dennis K. P. Ng
Keyword(s):  
Photodynamic Therapy ◽  
Alder Reaction ◽  
Diels Alder ◽  
Site Specific ◽  
Inverse Electron Demand ◽  
Diels Alder Reaction ◽  
Boron Dipyrromethene ◽  
Electron Demand

Inverse-electron-demand Diels–Alder reaction of a 1,2,4,5-tetrazine-substituted boron dipyrromethene with a biotin-conjugated trans-cyclooctene results in site-specific activation of the photoactivity of the former photosensitiser.

Orthogonal near-infrared upconversion co-regulated site-specific O 2 delivery and photodynamic therapy for hypoxia tumor by using red blood cell microcarriers

Biomaterials ◽  
2017 ◽  
Vol 125 ◽  
pp. 90-100 ◽  
Author(s):  
Peiyuan Wang ◽  
Xiaomin Li ◽  
Chi Yao ◽  
Wenxing Wang ◽  
Mengyao Zhao ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Near Infrared ◽  
Site Specific

scholarly journals Contrast enhanced MRI-guided photodynamic therapy for site-specific cancer treatment

2006 ◽  
Vol 56 (4) ◽  
pp. 761-767 ◽  
Author(s):  
Anagha Vaidya ◽  
Yongen Sun ◽  
Tianyi Ke ◽  
Eun-Kee Jeong ◽  
Zheng-Rong Lu
Keyword(s):  
Photodynamic Therapy ◽  
Cancer Treatment ◽  
Site Specific ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Specific Cancer ◽  
Mri Guided ◽  
Contrast Enhanced Mri

scholarly journals Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy

2016 ◽  
Vol 59 (7) ◽  
pp. 3204-3214 ◽  
Author(s):  
Pritam Thapa ◽  
Mengjie Li ◽  
Moses Bio ◽  
Pallavi Rajaputra ◽  
Gregory Nkepang ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Red Light ◽  
Combined Effects ◽  
Site Specific

Site-specific conjugation of single domain antibodies to liposomes enhances photosensitizer uptake and photodynamic therapy efficacy

Nanoscale ◽  
2016 ◽  
Vol 8 (12) ◽  
pp. 6490-6494 ◽  
Author(s):  
M. Broekgaarden ◽  
R. van Vught ◽  
S. Oliveira ◽  
R. C. Roovers ◽  
P. M. P. van Bergen en Henegouwen ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Single Domain ◽  
Site Specific ◽  
Therapy Efficacy ◽  
Single Domain Antibodies

scholarly journals PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug

2019 ◽  
Vol 308 ◽  
pp. 86-97 ◽  
Author(s):  
Mengjie Li ◽  
Luong Nguyen ◽  
Bharathiraja Subramaniyan ◽  
Moses Bio ◽  
Cody J. Peer ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Red Light ◽  
Pbpk Modeling ◽  
Site Specific

scholarly journals Nitric Oxide Antagonism to Anti-Glioblastoma Photodynamic Therapy: Mitigation by Inhibitors of Nitric Oxide Generation

Cancers ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 231 ◽  
Author(s):  
Jonathan Fahey ◽  
Albert Girotti
Keyword(s):  
Nitric Oxide ◽  
Photodynamic Therapy ◽  
Aminolevulinic Acid ◽  
No Synthase ◽  
Site Specific ◽  
Inos Activity ◽  
Cell Proliferation And Migration ◽  
Pharmacologic Inhibitors ◽  
And Migration ◽  
Proliferation And Migration

Many studies have shown that low flux nitric oxide (NO) produced by inducible NO synthase (iNOS/NOS2) in various tumors, including glioblastomas, can promote angiogenesis, cell proliferation, and migration/invasion. Minimally invasive, site-specific photodynamic therapy (PDT) is a highly promising anti-glioblastoma modality. Recent research in the authors’ laboratory has revealed that iNOS-derived NO in glioblastoma cells elicits resistance to 5-aminolevulinic acid (ALA)-based PDT, and moreover endows PDT-surviving cells with greater proliferation and migration/invasion aggressiveness. In this contribution, we discuss iNOS/NO antagonism to glioblastoma PDT and how this can be overcome by judicious use of pharmacologic inhibitors of iNOS activity or transcription.

Sign in / Sign up

Export Citation Format

Share Document